Agoracom Blog Home

Archive for the ‘Empower Clinics Inc.’ Category

VIDEO – Empower Clinics $CBDT.ca $EPWCF In Advanced Discussions With Large US Pharmacies As Proposed Acquisition Includes Products In 4,000 Canadian Pharmacies $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:57 PM on Thursday, June 3rd, 2021

As if today’s press release wasn’t good enough Empower Clinics Announces Major Expansion with Proposed Acquisition of Medisure Canada. Diabetes Tests and Devices Carried In 4,000 Pharmacies and Generated $1.9m in 2020 Revenue, shareholders also received this injection of confidence from CEO

Steve McAuley:

“As I’ve stated to our shareholders on multiple occasions throughout 2021, Empower is in the strongest position it has ever been and will continue to grow every aspect of our business unabated and without interruption. In addition to this acquisition, in the last 30 days alone we have announced expansions of our clinics, gone live on our KAI Saliva RT-PCR test with Air Canada and are very advanced on tripling the size of the KAI Medical Laboratory facility. We are hitting on all cylinders and well on our way to becoming a major vertically integrated healthcare company. I fully expect Empower to have continued strong business announcements in June and throughout 2021″

If that was all, it would be a great day … and it was with $CBDT closing up 16.5% on 7.5M shares to $0.53 … but then Steve shared some powerful information about leveraging this acquisition with large US pharmacies.  

Who did he name? 

Watch this great interview with CEO Steve McAuley.

VIDEO – Empower Clinics $CBDT.ca $EPWCF Shareholder Q&A With CEO Steve McAuley – Part 1 $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:23 PM on Friday, May 7th, 2021

PART 1 of Empower Clinics Shareholder Q&A with CEO Steve McAuley.

Topics Covered:

  • Annual Financials
  • KAI Labs
  • Clinics / Rexall
  • KAI Saliva
  • Pipelines

Part 2 next week.

VIDEO – Watch Our Latest Shareholder Q&A With @EmpowerClinics $CBDT $EPWCF

Posted by AGORACOM-JC at 9:06 PM on Thursday, April 15th, 2021

Empower $CBDT.ca $EPWCF Announces DTC Eligibility $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:16 AM on Thursday, April 15th, 2021
  • Company Stock Is Now More Accessible to U.S. Investors
  • United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).

VANCOUVER B.C. / April 15, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTC PINK:EPWCF) (“Empower” or the “Company”) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – is pleased to announce it is now eligible for Depository Trust Company (“DTC”) services in relation to Empower’s listing on the OTC.

United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).

“Convenience is a core part of Empower’s overall strategy for our approach to integrated healthcare, so our capital markets strategy should be the same. I’m thrilled that trading Empower’s shares will now be easier for existing and potential shareholders in the U.S.,” said Steven McAuley, Chairman & CEO of Empower. “Empower has a strong and growing presence in the United States market operationally as well as for investors. We’re confident that we will see enhanced trading liquidity as a result of our DTC eligibility.”

DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manages the electronic clearing and settlement of publicly traded companies. Empower is now eligible to be electronically cleared and settled through the DTC and is therefore considered “DTC eligible”. This electronic method of clearing securities streamlines the process of trading, enhances liquidity, and provides direct access to investors and brokers in the U.S. OTC capital markets.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab Receives Order for Up To 5,000 Covid-19 Tests from Two Film & Television Productions in Excess Of $750,000 $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, April 14th, 2021

  • Announced that Kai Medical Laboratory has received an order for COVID-19 RT-PCR tests that is anticipated to be in excess of $CAD 750,000 from two new film and television productions.

VANCOUVER, BC / April 14, 2021 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce that Kai Medical Laboratory (“KAI”) has received an order for COVID-19 RT-PCR tests that is anticipated to be in excess of $CAD 750,000 from two new film and television productions.

5,000 TEST ORDER FOR FILM & TELEVISION PRODUCTIONS REPRESENTS REPEAT ORDER BASED ON CONSISTENT PERFORMANCE OF KAI MEDICAL LAB

In early October, shortly after the acquisition of KAI, Empower announced an agreement to process approximately 1,000 COVID-19 RT-PCR tests for a major film & TV production over a 30-day period, with the possibility of more business upon successful completion of the initial tests.

On November 16, 2020 KAI received a repeat and record COVID-19 testing order for approximately 9,000 units in excess of $CAD 1,000,000 over a four-month period.

Today’s announcement represents a repeat Purchase Order of approximately 5,000 units to be processed over just a two-month period. The total revenue from this order is anticipated to be in excess of $CAN 750,000.

“Our team at KAI continues to deliver the type of performance to Tier-1 clients that is worthy of significant repeat business that serves as unequivocal validation of our capabilities,” said Steven McAuley, Chairman & CEO of Empower. “To this end, the magnitude of KAI’s growth and success cannot be overstated as it continues to focus on very active business development and product development, setting a path toward significant North American growth in the midst of tripling its size. KAI is well on its way to becoming a national brand supported by our strong working capital position and a team dedicated to performance.”

As of September 1st, KAI has already processed tests for multiple different film and television productions in key US markets including Los Angeles, Atlanta, New York, Dallas, earning the highest confidence of the industry.

KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED RAPID TEST GROWTH

On February 16th, Empower announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1”

KAI continues to progress on the design and build out of the laboratory expansion to prepare to meet upcoming demand in a number of areas. First, the continued processing of RT-PCR tests for film & television productions, commercial accounts and enterprise level clients. Second, the full e-commerce impact of KaiTests.com and the national direct-to-consumer marketing programs for KAI Saliva, an FDA, EUA authorized and Health Canada approved at-home Saliva COVID-19 RT-PCR Test. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into Canada and USA, or arriving in other countries that have similar executive travel orders.

Finally, KAI Labs continues the development of new direct-to-consumer test protocols that will expand the product offers on Kaitests.com throughout 2021 and beyond.

McAuley added “With each passing month Empower gains more strength and velocity in every aspect of our business from KAI Lab in Dallas to our rapidly expanding clinic operations in Canada and our direct-to-consumer products such as KAI Saliva. All of which are amply funded well into the future with our strongest balance sheet ever thanks to the receipt of more than $12,000,000 in warrant conversions as of last month. We are on a path, a trajectory towards building a great health and wellness company across North America, and I look forward to providing our shareholders with further specifics.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/759019-empower-clinics-kai-medical-lab-receives-order-for-up-to-5-000-covid-19-tests-from-two-film-television-productions-in-excess-of-750-000/messages/2311867#message

Empower $CBDT.ca $EPWCF Appoints Kai Medical Laboratory President Yoshi Tyler To Board of Directors $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:29 AM on Tuesday, April 13th, 2021
  • Announced it has appointed Ms. Yoshi Tyler to its board of directors.
  • With a professional and entrepreneurial background in healthcare, Ms. Tyler has more than 13 years of experience providing leadership at Pfizer, Inc., a Fortune 500 pharmaceutical company.
  • This experience has provided her with in-depth knowledge and industry insights to found and lead Kai Medical Laboratory towards unprecedented growth.

VANCOUVER, BC / April 13, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – is pleased to announce it has appointed Ms. Yoshi Tyler to its board of directors.

With a professional and entrepreneurial background in healthcare, Ms. Tyler has more than 13 years of experience providing leadership at Pfizer, Inc., a Fortune 500 pharmaceutical company. This experience has provided her with in-depth knowledge and industry insights to found and lead Kai Medical Laboratory towards unprecedented growth. Empower fully acquired Kai Medical Laboratory in October 2020.

“We are delighted to welcome Yoshi as a valued addition to our board of directors,” said Steven McAuley, Chairman & CEO of Empower. “Having diverse leadership continues to improve our company and since our acquisition of Kai Medical Laboratory, Yoshi has led her team to surpass initial growth forecasts and demonstrated an incredible work ethic and passion for excellence. I am privileged to now count Yoshi as a fellow board member in recognition of her talent, performance and passion.”

“I’m thrilled to be contributing to the growth of Empower at another level of the company,” said Yoshi Tyler. “After only a few months as part of the Empower team, I’ve witnessed the benefits of our synergies and know firsthand about the incredible potential we have to become a leading integrated health care company in North America.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/758939-empower-appoints-kai-medical-laboratory-president-yoshi-tyler-to-board-of-directors/messages/2311716#message

Empower Clinics $CBDT.ca $EPWCF Partners with Leading U.S. Digital Marketing Agency to Launch Direct-to-Consumer e-Commerce Solutions $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 8:19 AM on Thursday, April 8th, 2021

Snow Agency recognized as #1 U.S. digital marketing agency

  • Announced a partnership with Snow Agency to launch its direct-to-consumer (DTC) e-commerce solutions.
  • Snow Agency is a performance digital marketing and creative agency whose customized brand strategies and content production maximize the impact of direct response ads and creatives on Facebook/Instagram, Google/YouTube, Snapchat, and Email/SMS
  • Collaboration will allow Empower patients, existing and prospective, to benefit from an accessible, seamless and educative experience when purchasing at-home diagnostics test kits

VANCOUVER BC / April 8, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – today announced a partnership with Snow Agency to launch its direct-to-consumer (DTC) e-commerce solutions.

The Snow Agency is a performance digital marketing and creative agency whose customized brand strategies and content production maximize the impact of direct response ads and creatives on Facebook/Instagram, Google/YouTube, Snapchat, and Email/SMS. To date, they’ve brought in more than $250 million USD in sales for their clients. The Snow Agency has been recognized on Yahoo! Finance ranked as the #1 US Digital Marketing Agency & Digital Agency in January 2021 by Design Rush, a top B2B marketplace connecting brands with agencies.

The collaboration will allow Empower patients, existing and prospective, to benefit from an accessible, seamless and educative experience when purchasing at-home diagnostics test kits. Today patients can purchase at-home COVID-19 saliva test kits by phone or email at www.kaitests.com.

“Empower is committed to make our solutions as convenient as possible to all patients in North America. A DTC e-commerce solution is a key part of that solution.” said Steven McAuley, Chairman & CEO of Empower. “I am privileged to now count Snow Agency as a partner in our journey to deliver at-home testing solutions and empower patients to take control of their own health data. Even with vaccines, ongoing testing is desperately needed because more testing, along with mask-wearing and physical distancing, will get people back into offices, planes and classrooms and help catch cases that go undetected”.

“This partnership is really making a positive difference in people’s lives. We know that we can reach millions of consumers with success for brands. We see our partnership with Empower as our contribution from Snow Agency to help reopen the economy, allow people to travel with confidence and getting back to normal life.” said Dan Snow, CEO and Co-founder of Snow Agency.

“As a trained physician and a digital marketing entrepreneur, I fully believe in Empower’s at-home diagnostic testing solutions especially its integrated laboratory services at Kai Medical. It’s the time now to digitally transform healthcare, focus on accessibility and convenience for patients and save valuable time and money on stretched public health services. People will need to get tested regularly so we can all get back to normal” said Dr. Jonathan Snow, COO and Co-founder of Snow Agency.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Empower Clinics $CBDT.ca $EPWCF Reports Q1 2021 Patient Results With Year Over Year Growth of 460% $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:57 AM on Wednesday, April 7th, 2021

Patient count for March increased by 388%

  • Announced that patient counts increased by 460% in Q1 2021 (26,317) versus Q1 2020 (5,717).
  • Patient counts for the month of March increased by 388% versus the same period in 2020 with total patient counts of 8,379 in March 2021 compared to 2,160 in March 2020.

VANCOUVER BC / April 7, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce that patient counts increased by 460% in Q1 2021 (26,317) versus Q1 2020 (5,717). Patient counts for the month of March increased by 388% versus the same period in 2020 with total patient counts of 8,379 in March 2021 compared to 2,160 in March 2020.

“The delivery of world-class patient care is the number one priority for our team in all the markets we serve.” said Steven McAuley, Chairman & CEO of Empower. “I am so proud of our members’ daily effort and dedication to patients even in such uncertain times. For our team to achieve such significant year-over-year growth numbers is a testament to our ability to execute on our business plan to acquire patients and drive long-term shareholder value. I’m especially proud of the strong growth in the last month of Q1 which sets us up for continued growth in Q2 2021”

The Company has also issued a total of 800,000 stock options priced at $0.57 CAD to investor relation service providers and to a Director of the Company.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Source: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/758635-empower-clinics-reports-q1-2021-patient-results-with-year-over-year-growth-of-460/messages/2311070#message

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Participates In U.S. Federal Government RFP Bids To Test In Excess Of 50,000 Employees Using FDA Approved KAI Saliva COVID-19 At Home PCR Test $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 7:45 AM on Wednesday, March 24th, 2021
  • Announced the submission of bids on 5 significant US Federal Government Requests For Proposal to test in excess of 50,000 Federal employees using the Company’s KAI Medical COVID-19 Saliva Test
  • KAI Saliva is an FDA EUA authorized Saliva COVID-19 RT-PCR Test
  • In addition, RPF bids for over 10,000 of the approximate 50,000 employees are for ongoing testing, representing potential for significant recurring test revenues.

KAI Lab R&D, Development And Delivery Of KAI Saliva At-Home Test Kit Program, Along With Tripling Of KAI Lab Facility, Proves Valuable By Providing Empower With Ability To Bid and Accommodate Successful RFPs

VANCOUVER, BC / March 24, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the submission of bids on 5 significant US Federal Government Requests For Proposal (“RFP” or “RFPs”) to test in excess of 50,000 Federal employees using the Company’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”). KAI Saliva is an FDA EUA authorized Saliva COVID-19 RT-PCR Test.

In addition, RPF bids for over 10,000 of the approximate 50,000 employees are for ongoing testing, representing potential for significant recurring test revenues.

RFP BIDS INCLUDE FDA ITSELF, AIRPORT, SCHOOLS AND OTHER FACILITIES ACROSS THE COUNTRY

Empower has submitted US Government RFP bids for the following groups:

1. FDA – Food & Drug Administration

  • All Employees and contractors nationwide
  • Kai Saliva at-home test kit program
  • In excess of 38,000 kits required

2. Hanover County, Virginia Government

  • Public Schools
  • Regional Jail
  • Regional Library
  • 5,000 employees – Ongoing Testing
  • Kai Saliva at-home test kit program
  • Rapid antigen testing kits

3. Scranton, Pennsylvania Airport

Onsite testing facility for:

  • RT-PCR testing
  • Rapid Testing
  • Saliva RT-PCR testing
  • Ongoing testing

4. Alameda County, California

  • 3,100 employees and contractors – ongoing testing
  • Kai Saliva at-home test kit program

5. Durham County, North Carolina

  • 2,000 employees and contractors – ongoing testing
  • Kai Saliva at-home test kit program

RFP’S STEM FROM BIDEN ADMINISTRATION TO INVEST MORE THAN $12 BILLION TO EXPAND COVID-19 TESTING

These measures are part of President Biden’s strategy to increase COVID-19 testing nationwide as vaccinations increase.

As part of President Biden’s National Strategy for the COVID-19 Response and Pandemic Preparedness, the U.S. Department of Health and Human Services (HHS) will invest $10 billion from the American Rescue Plan to ramp up screening testing to help schools reopen, $2.25 billion to scale up testing in underserved populations, and provide new guidance on asymptomatic screening testing in schools, workplaces, and congregate settings.

Empower Clinics is ideally positioned with the right products.

KAI LAB AND KAI SALIVA COVID-19 PCR TEST COMPETITIVE ADVANTAGES IN RFP BIDS

Empower’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”) is an FDA EUA authorized Saliva COVID-19 RT-PCR Test that includes the following meaningful competitive advantages

  • KAI Salvia is an at-home based, self-administered COVID-19 RT-PCR saliva test kit that is easily accessed and self-administered. Visit www.kaitests.com
  • KAI Saliva provides travelers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into the United States or arriving in other countries that have strict executive travel orders.
  • KAI Saliva can provide major airlines and the tourism sector with the ability to provide solutions for travelers by making a KAI Saliva test as part of the ticketing purchase, the check-in process, in a kiosk, or on an e-commerce website.
  • As a result of continued rapid growth in 2021, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company then revised this planned expansion upwards on February 16th when it announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1.”

As a result of these competitive advantages, Empower believes the integrated solution of KAI Lab and KAI Saliva makes for a very strong offering.

“Our decision to triple the size of Kai Labs was in anticipation of positioning Kai Labs for growth and to be able bid on many significant U.S. Government contracts that are being awarded” said Steven McAuley, Chairman & CEO. “With investment in R&D and having substantial working capital available, I believe Kai Labs is deserving of national attention and has as a real opportunity to win these type of bids. Our new Kai Saliva test kit is in high demand and we are seeing more and more bids specifically requesting saliva-based COVID-19 testing products.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Empower Clinics $CBDT.ca $EPWCF Announces Receipt of Over $12,000,000 From Exercise of Warrants, Receives Full MDEL Status from Health Canada, Finalizes Lease Agreements for Initial Canadian Health Centers and Completes Lease for KAI Lab Expansion $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:36 AM on Friday, March 19th, 2021
  • Receipt of over $12M from exercise of warrants
  • Received Full MDEL Status
  • Finalizing leases for initial Canadian Health Centers
  • KAI Lab Expansion

Warrant Proceeds and Continued Business Development on Multiple Fronts Positions Empower for Continued and Rapid Growth in 2021

VANCOUVER, BC / March 19, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to provide a comprehensive corporate update with respect to the following matters:

RECEIPT OF OVER $12,000,000 FROM THE EXERCISE OF WARRANTS

Empower is pleased to announce the receipt of in excess of $12,000,000 from the exercise of warrants up to March 18, 2021, representing an increase of approximately $1,500,000 since the Company’s announcement on March 4, 2021 when the Company announced the receipt of approximately $10,500,000.

The receipt of these warrant proceeds, along with the Company’s expectations of generating continued significant revenue from its KAI Medical Laboratory, as well as, anticipated significant revenue from its national Canadian clinic launches and test kit sales over the next 12 months, provides Empower with the war chest necessary for continued rapid expansion in each of its divisions.

Steven McAuley, Chairman and CEO of Empower stated “Theodore Roosevelt said credit belongs to…who is actually in the arena, whose face is marred by dust and sweat…, I can attest that I am in the arena, our team members are in the arena, all focused, working hard for our shareholders, ensuring we continue to grow and reach new heights.” Mr. McAuley goes on to say “The company has never looked better, has never been more stable than today, has a great balance sheet and has clear vision for the future. Our leadership team, our entire team share a collective vision of growth, we care about patients, we are focused on technology, we understand the importance of what we are doing.”

RECEIPT OF FULL MEDICAL DEVICE ESTABLISHMENT LICENCE (MDEL) APPROVAL STRENGTHENS ABILITY TO SELL AND DISTRIBUTE KAI SALIVA AT-HOME COVID-19 RT-PCR TEST IN CANADA AND OTHER APPROVED TESTING PRODUCTS GOING FORWARD

Empower’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”) is an FDA EUA and Health Canada authorized at-home Saliva COVID-19 RT-PCR Test. KAI Saliva provides travelers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into Canada or arriving in other countries that have similar executive travel orders.

On January 21, 2021 Empower announced the filing of an MDEL for the purposes of importing, distributing and selling KAI Saliva which has experienced immediate success upon its launch on December 15, 2020 in the United States, with an initial soft launch order of 5,000 units and an order for the next 25,000 KAI Saliva PCR Test Kits with a sales value of approximately $5.5M.

On March 8, 2021 Empower announced it anticipates an order for the next 50,000 KAI Saliva test kits to prepare for demand.

Our MDEL can now be found on the Government of Canada MDEL ‘Live Listings’ page.

“We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders.” said Steven McAuley, Chairman & CEO. “As a result of receiving full MDEL status, Empower is engaged in meaningful discussions with several potential distribution partners across Canada. We fully expect KAI Saliva to enjoy the kind of success it is achieving in the United States.”

KAI Saliva can provide major airlines, cruise lines and the tourism sector with the ability to provide solutions for travelers by making a KAI Saliva purchase part of the ticketing purchase, the check-in process, in a kiosk, or on an e-commerce website.

NEGOTIATED LEASE AGREEMENTS FOR FIRST THREE HEALTH CENTRE LOCATIONS WITH BUILD OUT TO COMMENCE IN Q2 2021

On February 25, 2021 Empower announced the locations of the first three integrated health centers in Ontario, with each location anticipated to generate on average approximately $3,000,000 in annualized revenue, as follows:

1) Etobicoke, Ontario Approximately 2,700 sq.ft

2) London, Ontario Approximately 3,100 sq.ft

3) Etobicoke, Ontario Approximately 2,900 sq.ft

Empower is now advancing to the build-out phase with first completions and openings anticipated for 2Q 2021. Advanced discussions are currently underway on multiple additional locations as the Company advances the rollout of its national clinic expansion strategy.

Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

When each location is fully operational, Empower anticipates it can generate $2,560,000 – 3,600,000 in annual revenue per location.

COMPLETION OF LEASE AGREEMENT FOR KAI MEDICAL LABORATORY EXPANSION

KAI Medical Laboratory (“KAI LAB”), a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI LAB experienced significant growth in its first quarter under Empower (October 2020 – December 2020), with Q4 COVID-19 test units exceeding 6,000, far surpassing the 1,300 total units prior to acquisition.

Furthermore, on March 8, 2021, Empower announced KAI LAB had achieved the following significant milestones in 2021:

1. Each of January and February 2021 were record months for specimen collection and processing, with February delivering sequential growth of 27% over January 2021.

2. Exceeded single day specimen processing of 1,000 + units in February.

3. As a result of record months year to date 2021, the KAI LAB annual revenue run rate is now exceeding $10,000,000 with meaningful positive cash flow

As a result of this continued rapid growth in 2021, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company then revised this planned expansion upwards on February 16th when it announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1.”

KAI LAB has now completed the lease amendment with the landlord to take over the neighboring tenants’ space to triple the size of KAI LAB. Tenant’s improvements are set to commence immediately and before the end of March 2021. The expansion work will enable KAI LAB to hire additional staff across a wide array of roles, all to improve operational efficiency and to meet anticipated demand over the coming weeks and quarters.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across the US and Canada. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
CEO

CONTACTS:

Steven McAuley CEO
[email protected]
604-789-2146

Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.